This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Study of Tirzepatide (LY3298176) Compared to Dul...
Clinical trial

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes (SURPASS J-mono)

Read time: 2 mins
Last updated:7th May 2019
Identifier: NCT03861052

The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 636 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus
Actual Study Start Date: May 7, 2019
Estimated Primary Completion Date: April 17, 2021
Estimated Study Completion Date: April 17, 2021

- Experimental:
5 mg Tirzepatide
- Experimental: 10 mg Tirzepatide
- Experimental: 15 mg Tirzepatide
- Active Comparator: 0.75 mg Dulaglutide

Category Value
Date last updated at source 2019-07-03
Study type(s) Interventional
Expected enrolment 636
Study start date 2019-05-07
Estimated primary completion date 2021-04-17

View full details